We recently compiled a list of the 15 Best Biotech Stocks to Buy According to Billionaires. In this article, we are going to ...

Our time-tested methodologies were at work to help investors navigate the market well last week. Here are some of our key ...

Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...

The more we extend our horizon, the more likely it is that stocks will provide juicy returns. Investors can cash in by putting their money in exchange-traded funds (ETFs) that track the performance of ...

The latest trading day saw Amgen (AMGN) settling at $317.17, representing a +1.1% change from its previous close.

The general mood among these heavyweight investors is divided, with 70% leaning bullish and 20% bearish. Among these notable ...

The appeals court for the Federal Circuit upheld a lower court’s ruling, finding that Regeneron has not sufficiently ...

The phase 3 MINT trial evaluated the efficacy and safety of the drug in both muscle-specific kinase autoantibody ...

After raising an impressive 1.2 billion euros in 2024, European venture capital firm Sofinnova Partners is topping up its ...

Dr. Reddy’s Laboratories (RDY) and Alvotech (ALVO) announced that the U.S. FDA has accepted a Biologic License Application submission for AVT03. Read more here.

Amgen (NasdaqGS:AMGN) has recently garnered attention due to promising Phase 3 MINT trial results for UPLIZNA in treating ...